|12 Months Ended|
Dec. 31, 2020
|Income Tax Disclosure [Abstract]|
|INCOME TAXES||INCOME TAXES
On March 27, 2020, the CARES Act was enacted into law. The CARES Act allows for the deferral of income and social security tax payments, a five–year carryback for net operating losses (“NOLs”), changes to interest expense and business loss limitation rules, certain new tax credits, and certain new loans and grants to businesses. In connection with the CARES Act, we recognized $16.5 million in NOL carryback claims, of which approximately, $14.1 million was received during the fourth quarter of 2020. In connection with this claim, we received interest income of approximately $0.5 million which is included in miscellaneous income (expense). Our final refund claim for approximately $2.4 million is still outstanding and is included in taxes receivable on the consolidated balance sheet.
The difference between the year ended effective tax rate in income tax expense (benefit) and the Federal statutory rate of 21% is as follows:
The significant difference in rate is primarily due to the ability of the Company under the CARES Act to carryback 2018 and 2019 NOLs to a year with a 35% income tax rate. Other permanent differences include the research and development credit, compensation limits, and stock-based compensation.
Tax effects of temporary differences that give rise to significant portions of federal and state deferred tax assets and deferred tax liabilities were as follows:
We provided a valuation allowance in 2020 and 2019 against certain deferred tax assets because of uncertainties regarding their realization. In connection with the sale of AMAK, the Company recorded foreign tax expense, recognized as a foreign tax credit, of approximately $1.3 million (See Note 6) during the year ended December 31, 2020.
We file an income tax return in the U.S. federal jurisdiction and a margin tax return in Texas. We received notification from the Internal Revenue Service (“IRS”) in February 2020 on the selection of our December 31, 2017 tax return for audit. All audit requests are complete and the Company is expecting to receive confirmation of the audit closing without change. In prior years, we received notification that Texas selected our R&D credit calculations for 2014 and 2015 for audit. The state of Texas had suspended their examination while they comprehensively reviewed their audit procedures for consistency. During the fourth quarter of 2019, we received notice that Texas had completed their review of their procedures and initiated additional requests for information. The Company has timely responded to all requested information. We do not expect any changes related to the Federal or Texas audits. Our federal and Texas tax returns remain open for examination for the years 2016 through 2020.
We recognized no adjustment for uncertain tax positions. As of December 31, 2020, and 2019, no interest or penalties related to uncertain tax positions had been accrued.
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef